amosulalol has been researched along with Hypertension in 6 studies
amosulalol: RN given is for mono-HCl; structure given in first source
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To clarify the hemodynamic and endocrine mechanisms of the hypotensive effect of amosulalol, an alpha- and beta-adrenoceptor antagonist, 19 patients with essential hypertension received amosulalol (20-80 mg/day; average 48." | 7.68 | Hemodynamic and endocrine changes associated with hypotensive action of amosulalol in essential hypertension. ( Ando, K; Fujita, T; Noda, H; Ogata, E, 1992) |
| "A 42-year-old woman with pheochromocytoma received preoperatively a combined alpha- and beta-adrenoceptor blocking agent, amosulalol, exerting some inhibitory action on both receptors." | 7.68 | Failure of blood pressure control by a new combined alpha- and beta-blocking agent (amosulalol) in a patient with pheochromocytoma. ( Irisawa, C; Kawamura, S; Nakada, T; Watanabe, H; Yamaguchi, T, 1991) |
| " In our patient, both YM-09538 and bunazosin were effective in controlling severe hypertension preoperatively." | 4.77 | Periodic fluctuation of blood pressure and its management in a patient with pheochromocytoma. Case report and review of the literature. ( Ohno, M; Oishi, S; Sasaki, M; Sato, T; Umeda, T, 1988) |
| "To clarify the hemodynamic and endocrine mechanisms of the hypotensive effect of amosulalol, an alpha- and beta-adrenoceptor antagonist, 19 patients with essential hypertension received amosulalol (20-80 mg/day; average 48." | 3.68 | Hemodynamic and endocrine changes associated with hypotensive action of amosulalol in essential hypertension. ( Ando, K; Fujita, T; Noda, H; Ogata, E, 1992) |
| "A 42-year-old woman with pheochromocytoma received preoperatively a combined alpha- and beta-adrenoceptor blocking agent, amosulalol, exerting some inhibitory action on both receptors." | 3.68 | Failure of blood pressure control by a new combined alpha- and beta-blocking agent (amosulalol) in a patient with pheochromocytoma. ( Irisawa, C; Kawamura, S; Nakada, T; Watanabe, H; Yamaguchi, T, 1991) |
| "Amosulalol was approximately threefold more potent than labetalol and arotinolol in decreasing blood pressure (BP) in conscious SHR." | 1.29 | Characterization of the adrenoceptor antagonistic and antihypertensive activity of oral amosulalol, a combined alpha- and beta-adrenoceptor antagonist, in hypertensive rats. ( Honda, K; Inagaki, O; Nakagawa, C; Shibasaki, M; Sudoh, K, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inagaki, O | 1 |
| Sudoh, K | 1 |
| Shibasaki, M | 1 |
| Nakagawa, C | 1 |
| Honda, K | 1 |
| Ando, K | 1 |
| Noda, H | 1 |
| Ogata, E | 1 |
| Fujita, T | 1 |
| Inoue, Y | 1 |
| Yaga, K | 1 |
| Nishimura, M | 1 |
| Okafuji, K | 1 |
| Fujii, Y | 1 |
| Nagasaka, Y | 1 |
| Tanaka, M | 1 |
| Fujita, N | 1 |
| Kaku, K | 1 |
| Kaneko, T | 1 |
| Yamaguchi, T | 1 |
| Irisawa, C | 1 |
| Watanabe, H | 1 |
| Kawamura, S | 1 |
| Nakada, T | 1 |
| Sha, K | 1 |
| Furuya, H | 1 |
| Kuro, M | 1 |
| Kitaguchi, K | 1 |
| Yamagishi, N | 1 |
| Marunaka, S | 1 |
| Shimoyama, J | 1 |
| Okuda, T | 1 |
| Oishi, S | 1 |
| Sasaki, M | 1 |
| Ohno, M | 1 |
| Umeda, T | 1 |
| Sato, T | 1 |
1 review available for amosulalol and Hypertension
| Article | Year |
|---|---|
Periodic fluctuation of blood pressure and its management in a patient with pheochromocytoma. Case report and review of the literature.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Blood Pressure; Catecholamines; Ethanolamines; Hum | 1988 |
5 other studies available for amosulalol and Hypertension
| Article | Year |
|---|---|
Characterization of the adrenoceptor antagonistic and antihypertensive activity of oral amosulalol, a combined alpha- and beta-adrenoceptor antagonist, in hypertensive rats.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypert | 1994 |
Hemodynamic and endocrine changes associated with hypotensive action of amosulalol in essential hypertension.
Topics: Adult; Aldosterone; Antihypertensive Agents; Blood Pressure; Cardiac Output; Ethanolamines; Female; | 1992 |
Antihypertensive and metabolic effects of long-term treatment with amosulalol in non-insulin dependent diabetics.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Di | 1992 |
Failure of blood pressure control by a new combined alpha- and beta-blocking agent (amosulalol) in a patient with pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Antihypertensive Agents; Ethanolamines; Female; Humans; Hypertension | 1991 |
[Effects of a new alpha- and beta-adrenoceptor blocking drug (YM-09538) on intraoperative hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Ethanolamines; Female; Heart | 1988 |